Table 1 Baseline characteristics per treatment group, non-imputed data
MTX monotherapy (n = 523) | MTX + csDMARDs (n = 266) | MTX + glucocorticoids (n = 615) | ||||
|---|---|---|---|---|---|---|
Number | Number | Number | ||||
Age at first visit (years) | 522 | 47.9 (13.1) | 264 | 44.6 (10.9) | 479 | 48.3 (14.8) |
Gender (% female) | 520 | 78 | 266 | 83 | 609 | 81 |
Body mass index | 281 | 26.6 (6.7) | 184 | 27.6 (6.3) | 272 | 27.2 (6.0) |
Symptom duration at diagnosis median (IQR) | 451 | 365 (169–731) | 266 | 730 (365–1095) | 482 | 458 (181–1095) |
Rheumatoid factor (% positive) | 511 | 77 | 263 | 84 | 585 | 81 |
ACPA (% positive) | 300 | 72 | 98 | 85 | 342 | 76 |
Erosions present (% positive) | 305 | 40 | 62 | 55 | 293 | 52 |
ESR | 462 | 56.5 (33.0) | 241 | 69.3 (31.7) | 543 | 59.5 (35.5) |
CRP | 415 | 33.1 (33.9) | 219 | 40.3 (35.5) | 515 | 37.7 (37.1) |
HAQ | 439 | 1.0 (0.6) | 249 | 1.1 (0.6) | 506 | 1.3 (0.7) |
DAS | 314 | 3.7 (1.2) | 189 | 4.0 (0.96) | 347 | 3.9 (1.2) |
DAS 28 | 340 | 5.7 (1.5) | 192 | 6.2 (1.2) | 415 | 6.0 (1.5) |
MTX dose (% high dose) | 523 | 28 | 266 | 14 | 615 | 46 |
Follow-up duration (days) | 523 | 134 (28) | 266 | 135 (28) | 615 | 139 (31) |